MX357046B - Un metabolito de colesterol novedoso, 5-colesteno-3b-25-diol disulfato (25hcds) para terapia de trastornos metabolicos, hiperlipidemia, diabetes, enfermedad de higado graso y aterosclerosis. - Google Patents

Un metabolito de colesterol novedoso, 5-colesteno-3b-25-diol disulfato (25hcds) para terapia de trastornos metabolicos, hiperlipidemia, diabetes, enfermedad de higado graso y aterosclerosis.

Info

Publication number
MX357046B
MX357046B MX2014012324A MX2014012324A MX357046B MX 357046 B MX357046 B MX 357046B MX 2014012324 A MX2014012324 A MX 2014012324A MX 2014012324 A MX2014012324 A MX 2014012324A MX 357046 B MX357046 B MX 357046B
Authority
MX
Mexico
Prior art keywords
25hcds
cholesten
disulfate
diol
therapy
Prior art date
Application number
MX2014012324A
Other languages
English (en)
Other versions
MX2014012324A (es
Inventor
Ren Shunlin
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Publication of MX2014012324A publication Critical patent/MX2014012324A/es
Publication of MX357046B publication Critical patent/MX357046B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se ha encontrado que el 5-colesteno-3ß,25-diol disulfato (25HCDS) es un agonista de PPAR? y antagonista de LXR auténtico, y se usa para la terapia de trastornos de lípido y enfermedades inflamatorias que incluyen, sin limitación, enfermedad de hígado graso, enfermedad inflamatoria del intestino y enfermedad aterosclerótica.
MX2014012324A 2012-04-12 2013-03-15 Un metabolito de colesterol novedoso, 5-colesteno-3b-25-diol disulfato (25hcds) para terapia de trastornos metabolicos, hiperlipidemia, diabetes, enfermedad de higado graso y aterosclerosis. MX357046B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623414P 2012-04-12 2012-04-12
US201261623203P 2012-04-12 2012-04-12
PCT/US2013/031861 WO2013154752A1 (en) 2012-04-12 2013-03-15 A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS

Publications (2)

Publication Number Publication Date
MX2014012324A MX2014012324A (es) 2015-05-11
MX357046B true MX357046B (es) 2018-06-22

Family

ID=49328028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012324A MX357046B (es) 2012-04-12 2013-03-15 Un metabolito de colesterol novedoso, 5-colesteno-3b-25-diol disulfato (25hcds) para terapia de trastornos metabolicos, hiperlipidemia, diabetes, enfermedad de higado graso y aterosclerosis.

Country Status (21)

Country Link
US (6) US20150072962A1 (es)
EP (2) EP2836502B1 (es)
JP (4) JP6125610B2 (es)
KR (1) KR102180485B1 (es)
CN (2) CN106083976B (es)
AU (2) AU2013246435B2 (es)
BR (1) BR112014025081B1 (es)
CA (1) CA2867694C (es)
DK (1) DK2836502T3 (es)
EA (1) EA026683B1 (es)
ES (1) ES2641841T3 (es)
HK (1) HK1202294A1 (es)
HU (1) HUE035073T2 (es)
IL (1) IL234892B (es)
IN (1) IN2014KN02366A (es)
MX (1) MX357046B (es)
PL (1) PL2836502T3 (es)
PT (1) PT2836502T (es)
SI (1) SI2836502T1 (es)
WO (1) WO2013154752A1 (es)
ZA (1) ZA201406981B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
JP6125610B2 (ja) * 2012-04-12 2017-05-10 ヴァージニア コモンウェルス ユニバーシティ 代謝障害、高脂血症、糖尿病、脂肪性肝疾患及びアテローム性動脈硬化症の治療のための新規コレステロール代謝物、５−コレステン−３β，２５−ジオールジスルファート（２５ＨＣＤＳ）
LT3086793T (lt) * 2013-12-24 2022-08-25 Virginia Commonwealth University Deguonimi įsodrintų cholesterolio sulfatų (ocs) naudojimas inkstų disfunkcijai gydyti
TWI547280B (zh) * 2014-04-24 2016-09-01 長弘生物科技股份有限公司 穩定醫藥組合物
EP3166613A4 (en) 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
KR20170066507A (ko) * 2014-10-10 2017-06-14 버지니아 커먼웰스 유니버시티 약화된 렙틴 활성 및 지질 저장 장애 중 하나 이상에 의해 야기되는 장애의 치료용 산소첨가된 콜레스테롤 술페이트
WO2016103722A1 (en) * 2014-12-24 2016-06-30 Kyoto University Vitamin d3 derivatives and pharmaceutical use thereof
KR20230124756A (ko) * 2016-08-02 2023-08-25 버지니아 커먼웰스 유니버시티 염증성 피부 질환 및 피부 병변을 치료하기 위한 산소첨가된콜레스테롤 술페이트 (ocs) 의 용도
PT3494125T (pt) * 2016-08-02 2022-07-07 Durect Corp Composições compreendendo 5-colesten-3, 25-diol, 3-sulfato (25hc3s), ou seu sal farmaceuticamente aceitável, e, pelo menos, um oligossacárido cíclico
AU2017305305A1 (en) * 2016-08-02 2019-02-21 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
US11458146B2 (en) 2017-01-13 2022-10-04 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR101892577B1 (ko) 2017-04-21 2018-08-28 부산대학교 산학협력단 레블라스타틴 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 조성물
CN107286160A (zh) * 2017-06-05 2017-10-24 毛佳婧 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
EP3675888A4 (en) * 2017-08-31 2021-04-21 Ariel Scientific Innovations Ltd. S. SPINOSUM EXTRACT FOR FAT LIVER TREATMENT
CN114555044A (zh) * 2019-09-30 2022-05-27 度勒科特公司 酒精性肝炎的治疗
CN112294827B (zh) * 2020-11-12 2021-12-24 四川大学华西医院 5-胆甾烯 -3β-醇硫酸酯盐的用途
KR20230061860A (ko) 2021-10-29 2023-05-09 부산대학교 산학협력단 크산틴 유도체를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학적 조성물
WO2024008614A1 (en) * 2022-07-08 2024-01-11 Société des Produits Nestlé S.A. Use of 25-hydroxycholesterol for diabetic treatment and/or prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515810A (en) * 1999-04-30 2004-05-28 Arch Dev Corp Steroid derivatives
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
WO2007095462A2 (en) 2006-02-13 2007-08-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2009002873A1 (en) 2007-06-22 2008-12-31 Cvi Pharmaceuticals Limited Compounds, compositions and methods for reducing lipid levels
WO2011077245A2 (en) * 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
JP6125610B2 (ja) * 2012-04-12 2017-05-10 ヴァージニア コモンウェルス ユニバーシティ 代謝障害、高脂血症、糖尿病、脂肪性肝疾患及びアテローム性動脈硬化症の治療のための新規コレステロール代謝物、５−コレステン−３β，２５−ジオールジスルファート（２５ＨＣＤＳ）

Also Published As

Publication number Publication date
AU2017268646A1 (en) 2017-12-21
JP2015512937A (ja) 2015-04-30
AU2013246435B2 (en) 2017-10-05
KR102180485B1 (ko) 2020-11-18
BR112014025081B1 (pt) 2020-12-08
CN106083976A (zh) 2016-11-09
CN104220450B (zh) 2016-07-06
US20160355544A1 (en) 2016-12-08
BR112014025081A2 (pt) 2018-05-08
EP2836502A4 (en) 2015-08-19
AU2013246435A1 (en) 2014-10-16
HK1202294A1 (en) 2015-09-25
EA026683B1 (ru) 2017-05-31
SI2836502T1 (sl) 2017-11-30
JP6125610B2 (ja) 2017-05-10
EA201491859A1 (ru) 2015-02-27
WO2013154752A1 (en) 2013-10-17
US20150072962A1 (en) 2015-03-12
EP3239163A1 (en) 2017-11-01
EP2836502B1 (en) 2017-08-02
US20200157140A1 (en) 2020-05-21
CN104220450A (zh) 2014-12-17
JP2017160213A (ja) 2017-09-14
PL2836502T3 (pl) 2018-01-31
JP2021138713A (ja) 2021-09-16
DK2836502T3 (en) 2017-10-23
MX2014012324A (es) 2015-05-11
CA2867694A1 (en) 2013-10-17
US20180127457A1 (en) 2018-05-10
CN106083976B (zh) 2018-02-09
KR20150013520A (ko) 2015-02-05
EP2836502A1 (en) 2015-02-18
AU2017268646B2 (en) 2019-07-11
ZA201406981B (en) 2016-05-25
JP2019089777A (ja) 2019-06-13
ES2641841T3 (es) 2017-11-14
PT2836502T (pt) 2017-10-27
HUE035073T2 (en) 2018-05-02
US20190135856A1 (en) 2019-05-09
IL234892B (en) 2019-02-28
US20210238219A1 (en) 2021-08-05
IN2014KN02366A (es) 2015-05-01
CA2867694C (en) 2021-08-31

Similar Documents

Publication Publication Date Title
MX357046B (es) Un metabolito de colesterol novedoso, 5-colesteno-3b-25-diol disulfato (25hcds) para terapia de trastornos metabolicos, hiperlipidemia, diabetes, enfermedad de higado graso y aterosclerosis.
EP2716057A4 (en) METHOD OF DISPLAYING CONTENT ON A SECOND DEVICE CONNECTED WITH CONTENT PLAYED ON A FIRST DEVICE
IL220577A (en) Computer network server
SI3138415T1 (sl) Učinki metaboličnega odtisa posebno zasnovanih lipidnih komponent
EP2790095B8 (en) Method of displaying electronic document, and apparatus and computer program therefor
GB201403782D0 (en) Mass ingestion of content related metadata to an online content portal
EP2681622A4 (en) METHOD AND SYSTEM FOR A PROJECTOR-TYPE DISPLAY DEVICE FOR KEYBOARD TRAY AND PORTABLE COMPUTER
EP2821403A4 (en) ACRYLIC ACID ESTER DERIVATIVE AND METHOD FOR PRODUCING SAME, INTERMEDIATE AND PROCESS FOR PRODUCING SAME, HIGH MOLECULAR WEIGHT COMPOUND, AND PHOTOSENSITIVE RESIN COMPOSITION
EP2959897A4 (en) INTESTINAL TRACT PROTECTION AGENT CONTAINING HYDROXYLATED FATTY ACID
FR2959333B1 (fr) Procede et systeme d'adaptation d'un contenu textuel au comportement langagier d'une communaute en ligne
EP2688004A4 (en) METHOD FOR DISPLAYING ADVERTISEMENTS ON INTERNET RESOURCES BASED ON THEIR COMBINED CONTENT
EP2742503A4 (en) APPARATUS RELATING TO PHYSICALLY DISCRETE SIGN COMPONENTS
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina
HK1191836A1 (zh) 用於實施會陰切開術的設備和使用所述設備的方法
GB2491100B (en) Operating a server computer
IL239095A0 (en) A method for producing a display panel, as the display panel can be operated to allow the display of content on an escalator step
EP2791762A4 (en) FRONT ELEMENT FOR CAPACITIVE SCREEN PANELS OF ELECTRONIC DEVICES
FR2965957B1 (fr) Procede d'affichage sur un panneau de visualisation d'une table de cuisson
FR2960387B1 (fr) Bavoir couple a un set de table
GB201109913D0 (en) Lipid metabolism
AU2012904572A0 (en) Method of providing an advertisment to a portable electronic device
GB201106109D0 (en) Apparatus for displaying musical scores
GB201010225D0 (en) Interactive touch screen kiosk with built-in software for the use of excercise demonstration
GB201218456D0 (en) Positioning of electronic display screen equipement
AU336137S (en) Tablet computer stand

Legal Events

Date Code Title Description
FG Grant or registration